Prevalence and Antibiotic Susceptibility of Extended-Spectrum BetaLactamase (ESBL) And Metallo-Beta-Lactamase (MBL) Producing GramNegative Bacterial Isolates in a Tertiary Care Hospital, South Delhi
International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)
DOI: 10.25258/ijcpr.18.7.46 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Vansh Gupta und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) producing gram-negative bacteria (GNB) are a major cause of treatment failure in hospital and community settings, making local surveillance essential for guiding empirical therapy. This six-month cross-sectional study was conducted in the Department of Microbiology, HIMSR, and associated HAHC Hospital, Jamia Hamdard, New Delhi, between October 2023 and March 2024. A total of 280 gram-negative isolates from clinical specimens (urine, pus, blood, stool, body fluids and others) of outpatients and inpatients were identified using VITEK 2. Isolates were screened for ESBL and MBL by VITEK and disk-diffusion, and screen-positive isolates were confirmed by the Double Disk Diffusion Test (ESBL) and the Imipenem-EDTA Combined Disk Synergy Test (MBL). A subset of ESBL-positive and ESBL-negative isolates was further characterized by PCR for blaSHV, blaTEM and blaCTX-M genes. E. coli and Klebsiella spp. predominated, mostly from urine (47.8%) and pus (30.7%) samples. Of 280 isolates, 120 (42.8%) were confirmed ESBL producers and 47 (16.7%) were confirmed MBL producers, with E. coli leading both groups. Carbapenems, amikacin and nitrofurantoin retained the highest activity against ESBL producers, while colistin (95.7% sensitive) was most active against MBL producers, most of which resisted carbapenems. On PCR, blaCTX-M (56%) was the commonest ESBL gene, followed by blaTEM (44%); blaSHV was undetected. The study demonstrates a substantial burden of ESBL and MBLproducing GNB in this tertiary-care setting and underscores the need for continued surveillance, antimicrobial stewardship, and judicious carbapenem and colistin use.
Zitieren
APA
Gupta, V., Parihar, S., & Tewari, R. (2026). Prevalence and Antibiotic Susceptibility of Extended-Spectrum BetaLactamase (ESBL) And Metallo-Beta-Lactamase (MBL) Producing GramNegative Bacterial Isolates in a Tertiary Care Hospital, South Delhi. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.46
Vancouver
Gupta V, Parihar S, Tewari R. Prevalence and Antibiotic Susceptibility of Extended-Spectrum BetaLactamase (ESBL) And Metallo-Beta-Lactamase (MBL) Producing GramNegative Bacterial Isolates in a Tertiary Care Hospital, South Delhi. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.46
BibTeX
@article{Gupta2026,
author = {Gupta, Vansh and Parihar, Smriti and Tewari, Rachna},
title = {Prevalence and Antibiotic Susceptibility of Extended-Spectrum BetaLactamase (ESBL) And Metallo-Beta-Lactamase (MBL) Producing GramNegative Bacterial Isolates in a Tertiary Care Hospital, South Delhi},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {07},
doi = {10.25258/ijcpr.18.7.46}
}
EUVIMED